PCN32 Cost Savings With Bevacizumab Compared to Sunitinib in the Treatment of MRCC
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1133
https://www.valueinhealthjournal.com/article/S1098-3015(11)02695-7/fulltext
Title :
PCN32 Cost Savings With Bevacizumab Compared to Sunitinib in the Treatment of MRCC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02695-7&doi=10.1016/j.jval.2011.08.1133
First page :
A439
Section Title :
Cancer
Open access? :
No
Section Order :
1090